State Street
RVMD icon

State Street’s Revolution Medicines RVMD Stock Holding History

State Street’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$917M Buy
4,897,051
+494,389
+11% +$72.2M 0.03% 434
2026
Q1 		$428M Buy
4,402,662
+293,372
+7% +$29.6M 0.01% 600
2025
Q4 		$327M Sell
4,109,290
-1,145,349
-22% -$75.1M 0.01% 720
2025
Q3 		$245M Buy
5,254,639
+535,733
+11% +$21M 0.01% 838
2025
Q2 		$174M Sell
4,718,906
-1,086,013
-19% -$41.7M 0.01% 998
2025
Q1 		$205M Buy
5,804,919
+13,167
+0.2% +$534K 0.01% 875
2024
Q4 		$253M Buy
5,791,752
+512,168
+10% +$25.8M 0.01% 795
2024
Q3 		$239M Buy
5,279,584
+208,516
+4% +$9.08M 0.01% 813
2024
Q2 		$197M Sell
5,071,068
-314,952
-6% -$11.8M 0.01% 865
2024
Q1 		$174M Sell
5,386,020
-867,341
-14% -$25.7M 0.01% 953
2023
Q4 		$179M Buy
6,253,361
+2,385,751
+62% +$57.3M 0.01% 914
2023
Q3 		$107M Sell
3,867,610
-876,639
-18% -$26M 0.01% 1136
2023
Q2 		$127M Sell
4,744,249
-67,182
-1% -$1.65M 0.01% 1068
2023
Q1 		$104M Buy
4,811,431
+1,030,420
+27% +$25.4M 0.01% 1158
2022
Q4 		$90.1M Sell
3,781,011
-531,123
-12% -$11.3M 0.01% 1222
2022
Q3 		$85M Buy
4,312,134
+1,217,152
+39% +$26.7M 0.01% 1223
2022
Q2 		$60.3M Buy
3,094,982
+251,505
+9% +$4.9M ﹤0.01% 1504
2022
Q1 		$72.5M Buy
2,843,477
+88,844
+3% +$1.93M ﹤0.01% 1520
2021
Q4 		$69.3M Sell
2,754,633
-54,539
-2% -$1.54M ﹤0.01% 1579
2021
Q3 		$77.3M Buy
2,809,172
+460,582
+20% +$13.4M ﹤0.01% 1473
2021
Q2 		$74.5M Buy
2,348,590
+570,410
+32% +$19.9M ﹤0.01% 1541
2021
Q1 		$81.6M Sell
1,778,180
-12,952
-0.7% -$581K ﹤0.01% 1390
2020
Q4 		$70.9M Buy
1,791,132
+720,230
+67% +$28.5M ﹤0.01% 1412
2020
Q3 		$37.3M Buy
1,070,902
+808,613
+308% +$22.4M ﹤0.01% 1661
2020
Q2 		$8.28M Buy
262,289
+25,838
+11% +$812K ﹤0.01% 2527
2020
Q1 		$5.18M Buy
+236,451
New +$6.55M ﹤0.01% 2609

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street's RVMD Position: Q2 2026 in Review

State Street increased its Revolution Medicines (RVMD) stake by 11% in Q2 2026, buying an estimated $72.2M and bringing the position to 4,897,051 shares worth $917M. The position accounts for 0.03% of the portfolio, ranked #434.

State Street first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • State Street held 4,897,051 shares of Revolution Medicines worth $917M as of Q2 2026.
  • State Street bought 494,389 Revolution Medicines shares in Q2 2026, an estimated $72.2M.
  • Revolution Medicines made up 0.03% of State Street's portfolio in Q2 2026, its #434 holding.
  • State Street first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.